We are live on ! Find out more
INVA icon

Innoviva

143 hedge funds and large institutions have $4.12B invested in Innoviva in 2013 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more call options, than puts

Call options by funds: $28.7M | Put options by funds: $11.9M

33% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 48

8% more capital invested

Capital invested by funds: $3.82B → $4.12B (+$301M)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

5% less funds holding

Funds holding: 150143 (-7)

17% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 24

Holders
143
Holders Change
-7
Holders Change %
-4.67%
% of All Funds
4.64%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.19%
New
20
Increased
64
Reduced
48
Closed
24
Calls
$28.7M
Puts
$11.9M
Net Calls
+$16.8M
Net Calls Change
-$384M

INVA Hedge Fund Activity: Q3 2013 in Review

143 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Innoviva (INVA) for Q3 2013, worth a combined $4.12B — up 7.9% from $3.82B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of INVA and 20 opened new positions — a net loss of 4 holders — while 48 trimmed existing stakes and 64 added.

The largest buyer was Baupost Group, adding an estimated $76.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $174M.

  • 143 institutional investors held Innoviva (INVA) as of Q3 2013, down from 150 in Q2 2013.
  • Funds reported $4.12B of Innoviva stock for Q3 2013, up 7.9% quarter-over-quarter.
  • 20 funds opened new Innoviva positions in Q3 2013 and 24 closed out, a net change of -4 holders.
  • The largest Innoviva buyer in Q3 2013 was Baupost Group, an estimated $76.1M added.
  • The largest Innoviva seller in Q3 2013 was T. Rowe Price Associates, an estimated $174M sold.

Based on aggregated 13F filings for Q3 2013.